Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 69.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,142 shares of the biopharmaceutical company's stock after purchasing an additional 7,868 shares during the quarter. J. Safra Sarasin Holding AG's holdings in Alnylam Pharmaceuticals were worth $4,504,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Larson Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. OFI Invest Asset Management bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Versant Capital Management Inc lifted its holdings in shares of Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares during the last quarter. Finally, IFP Advisors Inc lifted its holdings in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 59,984 shares of company stock worth $16,864,347. Insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Chardan Capital restated a "buy" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Stifel Nicolaus lifted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective for the company. Citigroup raised their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Finally, StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $315.58.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $8.95 during midday trading on Friday, reaching $251.56. The stock had a trading volume of 835,531 shares, compared to its average volume of 879,273. The stock has a market cap of $32.72 billion, a PE ratio of -115.93 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a fifty day simple moving average of $247.37 and a two-hundred day simple moving average of $255.84. Alnylam Pharmaceuticals, Inc. has a 52-week low of $143.50 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.